



Title: Human papillomavirus (HPV) and related cancers; Prevention, Screening, Diagnosis and Priority research areas for LMICs

Date: 16-18 August 2022

Venue: The Bronte Garden Hotel, 132 Baines Avenue, Harare, Zimbabwe



Speakers' Profiles in order of presentations

<p>Prof. Rangarirai Masanganise</p>	<p>Professor Masanganise is the founding Chairperson, Department of Ophthalmology, Chairman, Department of Anatomy, Deputy Dean of College of Health Sciences before he was appointed Dean of the College in January 2018. Professor Masanganise is a renowned and passionate Ophthalmologist with particular interest in Optometry and Ophthalmic Nursing as they ensure provision of comprehensive eye care for patients. He spearheaded the establishment of the department of Ophthalmology to give the discipline the due professional and academic recognition and development. He has been instrumental in restructuring and programming the Faculty of Medicine and Health Sciences, transforming it from education 3.0 to education 5.0. Under his leadership, 5 new undergraduate programmes and 9 post graduate programmes were introduced.</p> <p>He is currently a member of the Radiation Authority of Zimbabwe Board of Directors and was the founding member of the People's Own Savings Bank, (POSB) Board of Directors. Professor Masanganise also spearheaded the establishment of BSc Optometry degree at the University of Zimbabwe and the Ophthalmic Nurse training at Pairirenyatwa Group of Hospitals. He initiated various strategic partnerships to mobilise resources for Ophthalmology and Optometry, in particular funding that led to the establishment of the College of Health Sciences Optometry Unit. He successfully negotiated a generous donation from CIMAS and also sourced ophthalmic equipment in the Main Theatres at Pairirenyatwa Group of Hospitals. Through his drive for development of the Faculty, Prof R. Masanganise ensured donations for laser equipment in the UZCHS Laser unit and wet lab from the Royal Dutch Embassy and Later Day Saints Charities, USA.</p> <p>Consistent with his passion for visual impairments, particularly for the disadvantaged members of society, Prof Masanganise initiated and participated in various Community Eye Care outreach programmes. Professor Masanganise is a recipient of the prestigious "Zimbabwe Medical Association Award" for his outstanding contribution to Ophthalmology in Zimbabwe. His research interests are in Ocular Diseases and Community Eye Health with peer reviewed publications to date</p>
<p>Dr Racheal Mandishora</p>	<p>Dr Racheal S. Dube Mandishora is a Molecular Virologist with over 15 years' experience in infectious disease research and laboratory diagnostics. Her specialty is in Infections Attributable Cancers and Cancer Epidemiology, particularly focusing her research on genomic characterization of known and novel viruses associated with cancers and understanding the biology of these viruses, their synergistic cooperation with other microorganisms and their contribution to human disease and cancer. Dr Mandishora's passion extends to implementing public health interventions that provide access to health services for preventing HPV attributable cancers. Her long term goal is to use her unique combination of basic science and epidemiology to investigate characteristics of onco- viruses, that can be used to develop preventative (vaccines) and diagnostic (laboratory assays) tools, at the same time translating them to tangible interventions for low-resourced communities. She is currently a Faculty Member at the University of Zimbabwe Faculty of Medicine and Health Sciences</p>



Title: Human papillomavirus (HPV) and related cancers; Prevention, Screening, Diagnosis and Priority research areas for LMICs

Date: 16-18 August 2022

Venue: The Bronte Garden Hotel, 132 Baines Avenue, Harare, Zimbabwe



	<p>and an Applied Research Scientist at Moffitt Cancer Center, having recently completed a post-doctoral fellowship at the International Agency for Research on Cancer (IARC).</p>
<p>Prof Lawrence Banks</p>	<p>Lawrence Banks received his Degree in Microbiology in 1981 and his PhD from Leeds University, UK in 1984. His term as Director-General of the ICGEB commenced on 1 July 2019. Scientific Coordinator of the ICGEB from 2016 – June 2019 he has been Group Leader of the Tumour Virology Laboratory at ICGEB Trieste, Italy since 1990. He is Editor of the Journal of Virology and FEBS Journal, and is on the Editorial Boards of Antiviral Therapy, Virus Research and Biological Chemistry. He has organised over 15 major international workshops on Human Papillomaviruses, on Leishmania and on DNA Tumor Viruses. He has served on Grant Review and PhD Examination Committees of numerous scientific organisations in Italy and abroad, including the Human Frontiers Science Program, DKFZ, and WHO IARC, and is Research Degree Coordinator in ICGEB for the Open University UK. His current research interest focuses on Human Papillomaviruses (HPVs), the causative agents of a number of human tumours, the most important of which is cervical cancer, a major cause of cancer-related death in women worldwide. His laboratory has made ground-breaking contributions to our understanding of how HPV enters the cell and subsequently brings about changes resulting in malignancy. He has published over 220 papers in peer-reviewed, international journals. To date 234 publications with h-index 57</p>
<p>Dr Jessica Islam</p>	<p>Jessica Y. Islam, PhD, MPH is a cancer epidemiologist and health services researcher focused on evaluating and intervening on cancer care disparities, at the intersection of infections and cancer. Her research interests include the prevention of cancers caused by infection and disparities in cancer care across the cancer continuum of people living with HIV in the US and globally. In her early work, Dr. Islam's research focused on identifying novel and effective methods for service delivery of cervical cancer screening in Kenya. She compared self-collection methods to test for HPV mRNA, a biomarker of increased risk for high-grade cervical lesions, and evaluated the cost-effectiveness of community health campaigns for cervical cancer screening in Kenya. Dr. Islam's work has also focused on addressing barriers and facilitators to HPV vaccination globally. Her research continues to focus on cervical cancer prevention through evaluating context-appropriate strategies to improve cervical cancer screening uptake in the US and globally. Dr. Islam's research program also focuses on evaluating cancer care outcomes among people living with HIV (PLWH) in the US using multi-payer health insurance claims and large cancer-focused databases. Her research focuses on the epidemiology of cancer among PLWH and evaluating disparities by race/ethnicity and HIV serostatus in curative and palliative cancer treatment receipt. In response to the COVID-19 pandemic, Dr. Islam has developed research projects to evaluate the behavioral, mental health, and social impact of the pandemic on cancer survivors and adults with chronic diseases broadly. In addition to her continued focus on infections and cancer, she plans to leverage her formative work on the effects of the COVID-19 pandemic to investigate the downstream effects on vulnerable populations, including PLWH.</p>



Title: Human papillomavirus (HPV) and related cancers; Prevention, Screening, Diagnosis and Priority research areas for LMICs

Date: 16-18 August 2022

Venue: The Bronte Garden Hotel, 132 Baines Avenue, Harare, Zimbabwe



<p>Prof. Sharon Prince</p>	<p>Sharon Prince is a Professor in Cell Biology and Head of the Department of Human Biology at the University of Cape Town in South Africa. Her research group is interested in identifying novel therapeutic interventions and drug targets for the treatment of various cancers including breast, cervical, and pancreatic cancers, melanoma, and sarcomas. Their special focus is on understanding the role and regulation of the developmentally important TBX2/3 transcription factors in cancers, the use of organometallic compounds as cancer drugs, and the repurposing of existing non-cancer drugs for cancer therapies.</p>
<p>Prof. Lynette Denny</p>	<p>I am a gynaecologic oncologist and have been working in the field of cervical cancer prevention in collaboration with colleagues from Columbia University, New York since 1995. We began our collaboration with the intention of evaluating alternative strategies for the prevention of cervical cancer in low resource settings. Cervical cancer was and remains the commonest cancer diagnosed among women living in poor countries due to the failure to either initiate or sustain cytology-based screening programmes. Our group pioneered the search for alternative protocols for the prevention of cervical cancer in community-based research sites in townships just outside of Cape Town. Since that time, I have had extensive research experience in cervical cancer prevention, including three cross-sectional studies comparing different screening tests (such as HPV testing and VIA to cytology), a prophylactic HPV vaccine trial in HIV positive women and a therapeutic vaccine trial in HPV negative women. We are currently engaged in an NCI (USA) funded trial evaluating screen and treat with the HPV Xpert Cepheid HPV test and have added evaluation of Automated Visual Evaluation of the cervix in addition to point of care HPV testing in a screen and treat approach. I was appointed the director of the SA Medical Research Council Gynaecological Cancer Research Centre, with 5 years of guaranteed funding. We are now in the next phase of the development of the Centre and have another 3 years of funding. I became head of Department of Obstetrics & Gynaecology in 2013 and handed over the leadership of our Gynaecological Cancer Unit to Dr Nomonde Mbatani who was second in charge. My tenure as Head of Obstetrics and Gynaecology, University of Cape Town, ended April 2022 and I am now a Professor, Special Projects, Department of O&G, Faculty of Health Sciences, UCT. In November I was awarded the Order of the Baobab by the President of SA for 'distinguished service' to our country. I was a participant in the WHO Clinical Guidelines Group designed to produce recommendation for secondary prevention of cervical cancer and use of HPV DNA/HPVmRNA testing as a primary screening test.</p>
<p>Prof. Zvavahera Mike Chirenje</p>	<p>Prof Mike Chirenje is a Gynaecologist and a Professor of Obstetrics and Gynaecology at the University of Zimbabwe (UZ) Faculty of Medicine and Health Sciences and University of California San Francisco. His long-standing research focus has included evaluating the optimal performance of cervical cancer screening tests in low resource settings, cervical cancer screening and impact of HIV on HPV infections among women, finding safe and effective biomedical HIV prevention strategies for women, STI testing and treatment. He is the Principal Investigator of the US National Institutes of Health (NIH) funded University of Zimbabwe -Clinical Trials Research Centre (UZ-CTRC) which conducts HIV clinical trials</p>



Title: Human papillomavirus (HPV) and related cancers; Prevention, Screening, Diagnosis and Priority research areas for LMICs

Date: 16-18 August 2022

Venue: The Bronte Garden Hotel, 132 Baines Avenue, Harare, Zimbabwe



<p>Dr Bothwell Guzha</p>	<p>Dr Bothwell Takaingofa Guzha is a board-certified Gynaecological Oncologist. He is a lecturer at the University of Zimbabwe in the department of Obstetrics and Gynaecology. He is passionate about cervical cancer prevention and treatment in low- and middle-income countries</p>
<p>Prof Anna Giuliano</p>	<p>Anna R. Giuliano, PhD, is the founding director of the Center for Immunization and Infection Research in Cancer (CIIRC) at the Moffitt Cancer Center in Tampa, Florida. Dr Giuliano's career had its inception in the relationship between human papillomavirus (HPV) infections and cervical cancer, and has evolved over the past 30 years to encompass penile, anal, and oral cancers in men, as well as other infectious diseases and their causal relationships with various cancers. Her work has contributed significantly to our understanding of HPV natural history and to HPV vaccine protection against multiple diseases in women and men. An expert in the field of cancer research she has led numerous studies conducted globally. Dr Giuliano was a contributor to the 1999 Institute of Medicine (IOM) report titled <i>The Unequal Burden of Cancer</i> and the 2005 International Agency for Research on Cancer (IARC) report that concluded for the first time that HPV is a cause of multiple cancers in women and men. In 2013, at the American Cancer Society (ACS) 100th anniversary, she was the recipient of the ACS Distinguished Achievement in Cancer Award. In 2018, she was selected for the ACS Clinical Research Professor Award for "Prevention of Infection-Related Cancers." In 2019, Dr. Giuliano received the American Society of Preventive Oncology (ASPO) <i>Fraumeni Distinguished Lifetime Achievement Award</i>. Dr Giuliano has authored >400 peer-reviewed publications.</p>
<p>Dr Massimo Tommasino</p>	<p>Massimo Tommasino is the scientific director IRCCS Istituto Tumori Giovanni Paolo II, Bari Italy with distinct interests in the characterization of the biological properties of oncoproteins from several human viruses, with a particular focus on cutaneous beta HPV types and their ability to deregulate the pathways involved in cellular proliferation and immune-response that are considered key events in virus-mediated carcinogenesis. Importantly, these studies led to the proposition of a novel model of virus-driven carcinogenesis in cooperation with environmental factors, in which the viral proteins act at an early stage of cellular transformation but become dispensable after full cancer development. He also has interests in epidemiological studies that are directed to the development of highly sensitive diagnostic assays for a large number of infectious agents (currently more than 150 human viruses). These assays led to the establishment of many collaborative epidemiological studies. Our collaborative network comprises more than 30 research groups from Europe, Asia, South America, North America and Canada. In particular, in the domain of mucosal HPV types and cancer risk, our multiplex diagnostic platform for oncogenic infections is core to a number of field studies of HPV and cancer, most notably those on HPV vaccine effectiveness in low-middle income countries.</p> <p>He has more than 340 scientific articles in peer-reviewed journals, e.g. <i>Oncogene</i>, <i>International Journal of Cancer</i>, <i>Virology</i>, <i>Journal of Virology</i>, <i>EMBO Report</i>, <i>FASEB Journal</i>, <i>Molecular and Cellular Biology</i>, <i>PNAS</i>, <i>PLoS Pathogens</i>, <i>Lancet</i>, <i>Lancet Oncology</i> under his belt. (h-index: 62)</p>



Title: Human papillomavirus (HPV) and related cancers; Prevention, Screening, Diagnosis and Priority research areas for LMICs

Date: 16-18 August 2022

Venue: The Bronte Garden Hotel, 132 Baines Avenue, Harare, Zimbabwe



<p>Dr Anna-Barbara Moscicki</p>	<p>Dr. Moscicki is a Professor of Pediatrics at University of California, Los Angeles, Chief, Division of Adolescent and Young Adult Medicine, Interim Chief, Division of General Pediatrics, Associate Executive Chair for Clinical Research, and Chair, Clinical Trials Committee for Pediatrics. She has 35+ years of experience working in the field of molecular epidemiology, behavioral studies of adolescents, mucosal immunology, and phase I and II clinical trials. Much of her work has focused on detailing the natural history of HPV in adolescents and young adults, primarily from a 25-year study “Natural History of HPV in Teens”. Her work has also involved children and adolescents living with HIV working with several national networks including Adolescent HIV and AIDS Research Network (AMHARN), Adolescent Therapeutic Trials Network, IMPAACT and Pediatric HIV/AIDS Cohort study. Much of her work has influenced public health policies involving cervical and anal cancer screening in general and vulnerable populations. She is past president of ASCCP, and has served on multiple national and international committees including NIH, PATH, WHO and SAGE. She is a current Board Member of IPVS and Chair of the Membership Committee.</p>
<p>Dr Lucy Gondogwe</p>	<p>Lucia Gondogwe is a medical practitioner specializing in Obstetrics and Gynecology.</p>
<p>Prof. Anna Giuliano</p>	
<p>Dr Megan Fitzpatrick</p>	<p>Dr Fitzpatrick’s research and professional focus is women’s cancer diagnosis and prevention, including screening program implementation, device development, and diagnostic test validation in low-resource settings, such as cervical cancer detection in traditionally underserved populations with a focus on Human Papillomavirus-related cancers.</p>
<p>Dr Chipo Gwanzura</p>	<p>Dr Chipo Gwanzura, MD, MMED, FCOG, is an Obstetrician Gynaecologist at the University of Zimbabwe and Parirenyatwa Group of Hospitals in Harare, Zimbabwe. She is a 2020 -2021 Fogarty University of California Global Health Institute GloCal Fellow, and current fellow on the Advancing Early Diagnosis of Cancer in Southern Africa (AWACAN-ED) study. She is an early career researcher whose goal is to provide quality evidence-based healthcare to women and contribute to finding solutions to reduce the burden of female morbidity and mortality in Zimbabwe, Sub-Saharan Africa and globally. Her current work focuses on postpartum haemorrhage prevention; and cervical, breast and colorectal cancer prevention. Her clinical focus is on minimally invasive surgery. She is undertaking sub-specialty training with the European Academy of Gynaecological Surgery. She is past vice-president of the World Association of Trainees in Obstetrics and Gynaecology (WATOG; 2018 - 2021). Currently she is Chair of Zimbabwe Society of Obstetricians and Gynaecologists (ZSOG) Public Relations Committee; committee member of the Zimbabwe Society of Gynaecological Endoscopy (ZSGE); Member of the Knowledge and Evidence Working Group of the Partnership for Maternal, Newborn and Child Health (PMNCH); and member of the Committee on Minimal Access Surgery of the International Federation of Gynaecology and Obstetrics (FIGO). She has presented at local and international conferences and published scientific articles</p>



Title: Human papillomavirus (HPV) and related cancers; Prevention, Screening, Diagnosis and Priority research areas for LMICs

Date: 16-18 August 2022

Venue: The Bronte Garden Hotel, 132 Baines Avenue, Harare, Zimbabwe



<p>Mr Saif Feroz Khan</p>	<p>Saif Feroz Khan was born and raised in Malawi and moved to the University of Cape Town, South Africa to pursue a BSc in Biochemistry and Genetics. He then joined the laboratory of Prof Sharon Prince for his honours in medical cell biology which he has continued into his PhD. His work investigates the molecular mechanisms underpinning cervical cancer and then targeting this signalling axis through a drug repurposing approach. Aside from his research, Saif is the postgraduate international student representative for the Faculty of Health Sciences and is the chairperson of the postgraduate cancer research initiative.</p>
<p>Dr Allen Matubu</p>	<p>Taguma Allen Matubu is a qualified Biomedical Scientist with 18 years of clinical trials research experience. He holds a Bachelor of Medical Laboratory Sciences, Master of Science in Clinical Epidemiology and PhD in Immunology. He currently serves as Laboratory Manager for the University of Zimbabwe-Clinical Trials Research Centre providing laboratory oversight for provision of diagnostic and safety monitoring tests for Clinical trial participants enrolled in phase I-IV clinical trials.</p>
<p>Prof Florence Mtambanengwe</p>	
<p>Prof Jephath Chifamba</p>	
<p>Dr Mazvita Muchengeti</p>	<p>Dr Mazvita Muchengeti (MChB, PhD) is a cancer epidemiologist and the Acting Head of Department of the South African National Cancer Registry. She is an honorary senior lecturer at the University of the Witwatersrand School of Public Health, Epidemiology and Biostatistics Division and a research associate at the South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University. She is the principal investigator of the South African HIV Cancer Match Study. She is a committee member of the African Cancer Registry Network research committee and leads the IARC-GICR collaborating centre for monitoring cervical cancer elimination in sub-Saharan Africa. Her interests lie in strengthening cancer surveillance and research in South Africa and the sub-Saharan African region and in exploring the role of infections in cancer development in African populations. She holds a medical degree from the University of Zimbabwe (2002), a Diploma in HIV management from the College of Medicine of South Africa (2005), a Masters in Epidemiology and Biostatistics from the University of the Witwatersrand (2011) and a PhD in epidemiology from the University of Bern, Switzerland (2016).</p>
<p>Dr Singini Mwiza</p>	<p>Mwiza Gideon Singini is a PhD- candidate in Cancer Epidemiology at Wits School of Public Health. For his PhD, he worked on a research hypothesis proving the utility of “serological markers for HPV types 16 and 18 late-early proteins as useful markers for detection of cervical cancer.” His research interests include serology biomarkers and HPV-related cancers.</p>



Title: Human papillomavirus (HPV) and related cancers; Prevention, Screening, Diagnosis and Priority research areas for LMICs

Date: 16-18 August 2022

Venue: The Bronte Garden Hotel, 132 Baines Avenue, Harare, Zimbabwe



<p>Dr Ntokozo Ndlovu</p>	<p>Dr. Ntokozo Ndlovu is a Clinical/Radiation Oncologist and Clinical Epidemiologist at the University of Zimbabwe Faculty of Medicine and Health Sciences (UZ-FMHS) where she is Chairperson of the Department of Oncology. She is also the Chairperson of the Non-communicable Diseases Research Group. Her career spans involvement in in the fields of research, human resources, and treatment capacity building through collaborative partnerships. She is a longstanding cancer advocate on equity of cancer care delivery at home and in the region.</p>
<p>Prof Joel Palefsky</p>	<p>Joel Palefsky, M.D., C.M., F.R.C.P.(C). Professor of Medicine and Infectious Diseases at the University of California San Francisco School of Medicine. He is the founder and director of the world's first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic Research and Education Center at the UCSF Cancer Center and is the vice-chair of the National Cancer Institute (NCI) AIDS Malignancy Consortium. He is the chair of the Anal Cancer /HSIL Outcomes Research (ANCHOR) Study and is past president of the International Papillomavirus Society.</p>
<p>Dr Anna Coghill</p>	<p>Anna E. Coghill, PhD, MPH is an Assistant Member in the Cancer Epidemiology Program at the H. Lee Moffitt Cancer Center & Research Institute. Her interest in the intersection between infectious agents and cancer began during her dissertation work focusing on HIV as a determinant of cancer patient survival at the UCI/Hutchinson Cancer Center Alliance in Uganda. This work suggested that HIV was not only related to cancer development but that it also played a role in how patients survived after a cancer diagnosis. Dr. Coghill's publications using the HIV/AIDS Cancer Match Study and National Cancer Database, as well as collaborations with the Brazilian National Cancer Institute, have established that HIV-infected cancer patients experience worse stage-specific survival than their HIV-uninfected counterparts. Her research program is now focused on identifying both healthcare-related and molecular reasons for this survival disparity, and she serves as the Moffitt Site Principal Investigator for the AIDS Malignancy Consortium, an NCI-funded clinical trials network to support innovative cancer prevention and treatment trials for PLWH and cancer.</p>
<p>Dr Peter Julius</p>	<p>Dr. Peter Julius is a consultant anatomic pathologist who teaches and conducts research at the School of Medicine of the University of Zambia. He is in his last year of doctoral studies. His research interests include oncogenic viruses, particularly human papillomaviruses, HIV/AIDS-related cancers, HIV/AIDS-related neuropathogenesis, and HIV/AIDS-related neurodegenerative disorders. The NCI and NIH support his research through a collaboration with Dr. Charles Wood of the Louisiana State University Health Sciences Center New Orleans, Dr. Peter Angeletti of the University of Nebraska- Lincoln Center for Virology, and the University Teaching Hospital. As a result of this collaboration, his team has established laboratories for molecular biology, virology, and pathology in Zambia. He has published thirteen (13) articles in peer-reviewed journals and hopes to publish more.</p>
<p>Dr Margaret Pascoe</p>	<p>Dr Margaret Pascoe is a public health clinician. She has been working in the public health sector in Zimbabwe for over 30 years, her focus is infectious diseases including sexually transmitted infections and HIV. She is the current medical director of the Newlands Clinic, an HIV care and treatment centre, and the president of the Zimbabwe HIV Clinicians Society.</p>



Title: Human papillomavirus (HPV) and related cancers; Prevention, Screening, Diagnosis and Priority research areas for LMICs

Date: 16-18 August 2022

Venue: The Bronte Garden Hotel, 132 Baines Avenue, Harare, Zimbabwe



<p>Dr Alltalents Murahwa</p>	<p>Dr Murahwa's career objective has always been to fight the spread of infectious diseases and cancer on both the biomedical and social front. I have 17 years' experience in medical laboratory sciences practice and public health research in medical virology, in Zimbabwe, Botswana and South Africa. My main skills are in medical virology and molecular techniques, next generation sequencing and use of bioinformatics in genomic analysis and discovery of novel pathogens.</p>
<p>Prof Margaret Borok</p>	<p>Margaret Borok, MD, FRCP is a Professor of Internal Medicine at the UZFMHS, with 20 years experience in clinical research and research management and manages the only referral clinic for patients with AIDS and Kaposi Sarcoma (KS). She is a committee member of the Strategies to Improve Kaposi Sarcoma (KS) Outcomes in Zimbabwe (SIKO) initiative. She sits on the international committee and KS working group of the AIDS Malignancy Consortium (AMC) under the NCI (National Cancer Institute) of the NIH. She has 27 publications that include peer-reviewed articles.</p>
<p>Dr Felix Mhlanga</p>	
<p>Dr Simbarashe Chinyowa</p>	<p>Dr Chinyowa is a general surgeon at Sally Mugabe Central Hospital, Harare, and a lecturer in the department of Surgical Sciences, UZ FMHS. A past AMC fellow (2018), he is an early career researcher with interest in anal HPV infections and invasive anal cancer. His passion is to see increased awareness, prevention and early treatment of anal cancer in low-resource environments.</p>
<p>Dr Deckster T Savadye</p>	<p>Dr Deckster Tonny Savadye is the Chief Executive Officer and Registrar of the National Biotechnology Authority (NBA). He holds a Doctor of Philosophy from the University of Zimbabwe (as part of his doctoral studies, Dr Savadye conducted research work at the International Livestock Research Institute (ILRI) based in Nairobi, Kenya, where he was a Graduate Fellow), Masters of Science Degree in Biotechnology (Awarded with merit), and Bachelor of Science (Honours) in Biological Sciences. He is an experienced molecular biologist with more than 20 years of post-doctoral experience.</p>

Meet the team: The Organizing Committee

<p>Racheal Mandishora</p>	<p>Listed as speakers</p>
<p>Carol S Tazvinga</p>	<p>Caroline Sungano Tazvinga holds a Diploma in Secretarial Studies, an Advanced Diploma in Office Management and an IATA Diploma in Travel</p>



Title: Human papillomavirus (HPV) and related cancers; Prevention, Screening, Diagnosis and Priority research areas for LMICs

Date: 16-18 August 2022

Venue: The Bronte Garden Hotel, 132 Baines Avenue, Harare, Zimbabwe



	<p>and Tourism. She is working towards a Degree in Human Resources. Caroline is the Administrative Assistant for the University of Zimbabwe Faculty of Medicine and Health Sciences - Partnership in Education Training and Research Advancement (PETRA) program and Enhancing Non-communicable diseases Research and Innovation Capacity in Harare, Zimbabwe (ENRICH) which are National Institutes of Health funded training programs. She was instrumental in the administrative setting up and implementation of the of the Novel Education Clinical Trainees and Researchers (NECTAR) from 2010- 2015 and the Promoting Excellence in Research and Faculty Enhanced Career Training (PERFECT) from 2015-2022. Caroline was involved in the successful writing of a competitive call to host the 5th Annual AFREhealth Symposium. She was the vice secretary in the organising committee for the symposium held in August 2022 in Harare. She is the current 1st runner up of the Institute of Administration and Commerce (IAC) Office Manager of the year 2022/2023. Caroline is a go-getter with excellent communication and interpersonal skills.</p>
Oppah Kuguyo	<p>Ms Oppah Kuguyo is a PhD candidate at the University of Zimbabwe. Her research focuses on four main aspects; (i) genetic and non-factors associated with distinctive HPV genotypes in a cervical cancer cohort, (ii) the role of distinct HR-HPV in predicting treatment response in patients with cervical cancer (iii) pharmacogenomics of cervical cancer, and (iv) establishing a bioresource for future genomics research on HPV and cervical cancer. Ms Kuguyo was a recipient of the Organisation for Women in Science in the Developing World (OWSD) for the PhD training program and was recognized at the Merck Foundation African Researchers Summit in 2021 with the Best Young African Researcher Award. As it stands, Ms Kuguyo, is looking for postdoctoral research opportunities in HPV-related cancers.</p> <p>In addition, Oppah has experience in organizing and co-ordinating research conferences as part of her work at the Human, Health and Hereditary research in Africa (H3Africa) co-ordinating centre.</p>
Thokozile Mashaah	<p>Ms Thokozile Mashaah is the Deputy Director and Grants Administrator at the University of Zimbabwe Faculty of Medicine and Health Sciences Research Support Centre. She has been instrumental in the establishment of the RSC and has supported the pre-award and post-award process. Through her work, she has trained faculty and administrators in grant writing and management. Thokozile is also a Technical Subcommittee member for the AAS Good Research Management Practice (GRMP) and leads the AFREhealth RSC Technical Working Group. Prior to joining the RSC, she was a Programmes Officer in a regional NGO. She holds a MSc in Population Studies from University of Zimbabwe and is a PhD candidate with the University of Zimbabwe.</p>